Vera Therapeutics Says TRUTAKNA Met All ORIGIN 3 Endpoints
The company said TRUTAKNA met the primary and all prespecified endpoints in IgA nephropathy, with safety generally comparable to placebo. It plans to file a supplemental BLA in Q4 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.